findmyKOL

Bethany Karl, DO

Basic profile

University of California San Diego

ORCIDNone on fileNPI
RegionSan Diego, CA · WestSpecialtyNephrologyFocusNephrology
ActivityNot yet indexedfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPaymentsNone reportedNIH fundingNot yet indexedWhy? →

Bethany Karl is a Nephrology physician affiliated with University of California San Diego. OpenAlex indexes 10 publications with 644 citations (h-index 3); ClinicalTrials.gov lists 1 registered study matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
10publications

Distinct works indexed by OpenAlex.

644citations

Total citations across indexed works.

3h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    45.4%
    Calcium channel blocker12.8%
    Amlodipine Besylate52%Nifedipine Er48%
    Part D29 patients
    Angiotensin receptor blocker (ARB)7.2%
    Losartan Potassium63%Valsartan37%
    Part D<11 patients

    + 7 more classes in this area

  • Metabolism & gastrointestinal

    31.9%
    SGLT2 inhibitor10.8%
    Farxiga66%Jardiance22%Invokana12%
    Part D<11 patients
    Vitamin D3 Analog9.8%
    Calcitriol100%
    Part D25 patients

    + 6 more classes in this area

  • Other

    8.5%
    Phosphate Binder6%
    Sevelamer Carbonate100%
    Part D16 patients
    Drugs for treatment of hyperkalemia and hyperphosphatemia2.5%
    Lanthanum Carbonate50%Velphoro50%
    Part D<11 patients
Where care is delivered (Part B)75.3% facility · 24.7% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”